UBS AM’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $31.3M | Buy |
2,775,349
+329,542
| +13% | +$3.71M | 0.01% | 867 |
|
|
2025
Q1 | $24.7M | Buy |
2,445,807
+34,341
| +1% | +$347K | 0.01% | 875 |
|
|
2024
Q4 | $28.5M | Buy |
2,411,466
+104,288
| +5% | +$1.23M | 0.01% | 819 |
|
|
2024
Q3 | $26.6M | Buy |
2,307,178
+762,953
| +49% | +$8.8M | 0.01% | 843 |
|
|
2024
Q2 | $16.3M | Buy |
1,544,225
+399,797
| +35% | +$4.23M | ﹤0.01% | 937 |
|
|
2024
Q1 | $12.1M | Sell |
1,144,428
-2,204
| -0.2% | -$23.2K | ﹤0.01% | 938 |
|
|
2023
Q4 | $12.9M | Buy |
1,146,632
+97,432
| +9% | +$1.09M | 0.01% | 905 |
|
|
2023
Q3 | $12.3M | Buy |
1,049,200
+749,191
| +250% | +$8.75M | 0.01% | 888 |
|
|
2023
Q2 | $2.21M | Hold |
300,009
| – | – | ﹤0.01% | 1596 |
|
|
2023
Q1 | $2.21M | Sell |
300,009
-26,033
| -8% | -$192K | ﹤0.01% | 1596 |
|
|
2022
Q4 | $2.61M | Buy |
326,042
+53,493
| +20% | +$427K | ﹤0.01% | 1413 |
|
|
2022
Q3 | $878K | Buy |
272,549
+35,783
| +15% | +$115K | ﹤0.01% | 2041 |
|
|
2022
Q2 | $964K | Buy |
+236,766
| New | +$964K | ﹤0.01% | 1986 |
|